Clinical Trials Logo
  1. Home
  2. House Dust Mite Allergy
  3. NCT00263549
  4. Details
NCT00263549 Clinical Trial

Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

House Dust Mite Allergy Clinical Trial

Official title:
Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00263549
Other study ID # Al0201NH
Secondary ID
Status Completed
Phase Phase 4
First received December 8, 2005
Last updated February 8, 2013
Start date September 2002
Est. completion date February 2006

Study information
Verified date February 2013
Source Allergopharma GmbH & Co. KG
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date February 2006
Est. primary completion date February 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Positive skin prick test to house dust mite,

- Positive RAST test to house dust mite,

- Positive provocation test result to house dust mite,

Exclusion Criteria:

- Serious chronic diseases,

- Other perennial allergies

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Biological:
• House dust mite Novo Helisen Depot

Locations
Country Name City State
Germany Allergopharma GmbH & Co. KG Reinbek

Sponsors (1)
Lead Sponsor Collaborator
Allergopharma GmbH & Co. KG

Country where clinical trial is conducted

Germany, 

See also
  Status Clinical Trial Phase
Completed NCT02443805 - Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR Phase 3
Completed NCT03094845 - Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients Phase 2
Completed NCT01930461 - Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma Phase 2
Completed NCT01923792 - ToleroMune House Dust Mite Follow on Study N/A
Completed NCT00574704 - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis Phase 2
Completed NCT05019209 - Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients N/A
Recruiting NCT02238353 - AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Phase 4
Completed NCT01454544 - A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet Phase 3
Terminated NCT01777464 - Role of the Central Nervous System in Allergic Rhinitis N/A
Completed NCT00574223 - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis Phase 2
Completed NCT02345278 - SUBLIVAC FIX Mite Mixture Dose Tolerability Study Phase 1/Phase 2
Completed NCT01608243 - Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts Phase 1
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01134757 - Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction. N/A
Recruiting NCT05395689 - Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM Phase 3
Not yet recruiting NCT05400811 - Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis Phase 3
Not yet recruiting NCT05450289 - The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy N/A
Recruiting NCT05174689 - Epigenetic Regulation of Exercise Induced Asthma N/A
Terminated NCT04874714 - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis Phase 3
Completed NCT00380926 - Fish Oil and Asthma in House Dust Mite Allergy Phase 2/Phase 3

External Links